In the TOP-1 trial, omitting RT and endocrine therapy after breast-conserving surgery yielded a 14.8% 5-year local recurrence risk in women aged 70 and older.
|Videos|August 22, 2017
Using Molecular Tools to Guide Breast Cancer Treatment
Author(s)Philippe L. Bedard, MD
This video examines the use of molecular diagnostics for guiding adjuvant endocrine therapy in patients with breast cancer.
Advertisement
In this video, Philippe L. Bedard, MD, of Princess Margaret Cancer Centre in Toronto, Canada, discusses molecular tools for guiding adjuvant endocrine therapy in patients with breast cancer.
Bedard gave a presentation on this subject during an education session at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting.
Advertisement
Related to this article
A multidisciplinary panel discusses the effects of GLP-1 RA use during breast cancer care along with insurance denials, costs, and other critical areas.
“The more representation, the more people we have participating in clinical trials, the more applicable the data,” said Patricia A. Robinson, MD.
Six-year NATALEE data show ribociclib plus an NSAI reduced the risk of death by 19% vs NSAI alone in HR+/HER2- early breast cancer.
Final NSABP B-42 data show 5 additional years of letrozole improved DFS, BCFI, and distant recurrence vs placebo at 15 years, with no OS difference.
Hope S. Rugo, MD, FASCO, and Irene M. Kang, MD, discussed ASCENT-03, -04, and TROPION-Breast02 data, sequencing, and toxicity in metastatic TNBC.
Oana Danciu, MD, explained why phase 1 breast cancer trials are moving earlier in the treatment course and how disease stability guides patient selection.
“What has changed is that we are bringing the phase 1 trials earlier in the course of treatment for our patients,” said Oana Danciu, MD.
Advertisement
Advertisement
Trending on CancerNetwork
1
Ivonescimab Combo Improves Survival in Advanced Biliary Tract Cancer
2
Osimertinib/Savolitinib Improves Survival in MET-Altered EGFR-Mutant NSCLC
3
Sonesitatug Vedotin Improves OS in Pretreated CLDN18.2+ Gastroesophageal Cancer
4
How Can Functional Modeling, AI Accelerate Translational Breast Cancer Research?
5